Translation PA

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

<u> </u>
/
ÜΞ
\supset
တ္ဆ
2
\approx
600/29
8

Applicant's or agent's file reference DC/BR70208	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/FR00/01728	International filing date (day mo 21 June 2000 (21.06		
International Patent Classification (IPC) or no C12Q 1/70	ational classification and IPC		
Applicant	BIO MERIEUX		
Authority and is transmitted to the ap	oplicant according to Article 36.	red by this International Preliminary Examining	
been amended and are the ba	ied by ANNEXES, i.e., sheets of sis for this report and/or sheets co	the description, claims and/or drawings which have	
3. This report contains indications relating to the following items:			
Date of submission of the demand 05 January 2001 (05.01.	ĺ	ompletion of this report 11 September 2001 (11.09.2001)	
Name and mailing address of the IPEA/EP	Authorized	d ofTicer	
Facsimile No.	Talanhana	. N.	

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/FR00/01728

I. Basis of the report		
1. This report has been drawn under Article 14 are referred to	on the basis of (Replacement shoto in this report as "originally filed	veets which have been furnished to the receiving Office in response to an invitation d" and are not annexed to the report since they do not contain amendments.):
the international	al application as originally filed	d.
the description.	. pages1-15	, as originally filed.
	pages	, filed with the demand.
	pages	, filed with the letter of
· · ·	pages	filed with the letter of
the claims.	Nos. 1-5	as originally filed.
_	Nos.	. as amended under Article 19.
	Nos.	. filed with the demand.
	Nos. 6-14	. filed with the letter of 31/07/2001
		. filed with the letter of
the drawings.	sheets/fig	, as originally filed.
	sheets/fig	filed with the demand.
	sheets/fig	. filed with the letter of
	sheets/fig	. filed with the letter of
2. The amendments have result	ted in the cancellation of:	
the description.	pages	_
the claims.	Nos	_
the drawings.		
This report has been e to go beyond the discle	stablished as if (some of) the arosure as filed, as indicated in the	mendments had not been made, since they have been considered he Supplemental Box (Rule 70.2(c)).
4. Additional observations, if no	ecessary:	
		·
		·
	·	
	•	

INTERNATIONAL PALLIMINARY EXAMINATION REPORT

International application No. PCT/FR 00/01728

Reasoned statement under Article 35 citations and explanations supporting		inventive step or industrial app	licability;
Statement			
Novelty (N)	Claims	1-14	YES
	Claims		NO
Inventive step (IS)	Claims	1-14	YES
	Claims		NO
Industrial applicability (IA)	Claims	1-14	YES
	Claims		NO

- 2. Citations and explanations
 - 1. The following documents are referred to:
 - D1 WO-A-96/08580
 - D2 Antimicrobial Agents and Chemotherapy, **42**(12), Dec. 1998, 3256-3265
 - D3 Antimicrobial Agents and Chemotherapy, 40(11), Nov. 1996, 2535-2541
 - D4 Journal of Virology, 69(9), Sept. 1995, 5431-5436
 - D5 WO-A-90/14842
 - D6 Journal of Biochemistry, **268**(15), June 1993, 11939-11945 (this document is cited by the applicant).
 - 2. D1 describes a method for determining, in a biological sample taken from a patient contaminated with HIV 1, a possible resistance of the HIV 1 viral strain to treatment with an anti-protease agent, which involves searching for the presence of at least one position in the peptide sequence associated with resistance (D1, claims). D1 mentions two mutations which are particularly effective in inducing resistance: KN55N and L90M (D1, page 45, lines 16-19).

International application No. PCT/FR 00/01728

'Similar methods are described in D2-D4:

D2 refers to the detection and identification of mutations in the peptide sequence of HIV 1 protease, which are associated with increased resistance to the anti-protease agent indinavir. The most significant mutations appear at positions 63, 84 and 90 and concern the-L63P--184V and L90M substitutions (D2: abstract).

 ${\tt D3}$ describes a method for detecting mutations in ${\tt HIV}$ 1 protease associated with resistance to protease inhibitors. The method is applied to blood samples and the mutations concern positions 10, 46, 48, 63, 82, 84 and 90 (abstract and results).

D4 describes mutations at positions 48 and 90 of HIV 1 protease which increase resistance to the anti-protease agent Ro 31-8959 (abstract).

- The methods defined in independent Claims 1 and 8 differ from the method known from D1-D4 in that the HIV 1strain is replaced by HIV 2. The subject matter of independent Claims 1 and 8 is therefore novel (PCT Article 33(2)).
- 2.3 D5 describes a vaccine against HIV containing a modified protein of HIV 2. D5 discloses inter alia a nucleic acid sequence including the sequence CCA AGA ATA suitable for use in the method claimed in the present application (D5, page 7, line 4, and page 18, line 3). However, this sequence contains more than 40 nucleotides. Furthermore, none of the cited prior art documents describes the other samples defined in independent Claims 7 and 14. Consequently, the subject matter of these claims is also novel (PCT Article 33(2)).

Form PCT/IPEA/409 (Box V) (January 1994)

protease agents.

- 3. The problem addressed by the present invention can therefore be considered to be that of providing a method and nucleotide samples for identifying mutations which render proteases of the HIV 2 strain resistant to anti-
- 3.1 At-the-time-of the invention, the amino acid sequence of the HIV 2 protease would have been known to a person skilled in the art (as indicated on page 2 of the application). He would also have been familiar with the fact that the sequences of the proteases of HIV 1 and HIV 2 are relatively conserved. At first glance, it would therefore appear to be obvious for a person skilled in the art to follow the method of documents D1-D4 and, by virtue of the conservation between HIV 1 and HIV 2, to diagnose mutations in known positions, namely positions 10, 46, 48, 55, 63, 82, 84 and 90, thereby obtaining a method and nucleotide samples corresponding to Claims 1, 7, 8 and 14. However, as illustrated by D6 (summary), it was also known that even apparently slight differences between the HIV 1 and HIV 2 strains could result in major differences. For instance, mutation of a single amino acid will not provide the predicted resistance but will
- 3.2 In view of these facts, a person skilled in the art could not have anticipated the present invention as defined in independent Claims 1, 7, 8 and 14 and in dependent Claims 2-6 and 9-13.

 The subject matter of Claims 1-14 is therefore inventive (PCT Article 33(3)).

increase sensitivity to a protease by a factor of 100.

INTERNATIONAL PREZIMINARY EXAMINATION REPORT

ternational application No.
PCT/FR 00/01728

VII.	Certain	defects	in the	e international	application

The following defects in the form or contents of the international application have been noted:

Contrary to the requirements of PCT Rule 5.1(a)(ii), the description does not indicate the relevant prior art disclosed in D1-D5, nor does it cite these documents.

Form PCT/IPEA/409 (Box VII) (January 1994)



REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

TITLE OF INVENTION

BIO MERIEUX

FRANCE

3 Avenue Victoria 75004 PARIS - FRANCE

FRANCE

TONNELLIER Jean-Claude

all designated

States

applicant(s) before the competent International Authorities as:

all designated

States

Box No. I

Box No. II APPLICANT

State (that is, country) of nationality:

State (that is, country) of nationality:

This person is applicant for

the purposes of:

Name and address:

This person is applicant

for the purposes of:

International Application No.
International Filing Date
Name of receiving Office and "PCT International Application"

iving Office use only

Applicant's or agent's file reference (if desired) (12 characters maximum) DC/BR70208 SEARCH METHOD FOR RESISTANCE TO ANTI-PROTEASES OF A STRAIN OF THE HIV-2 VIRUS FROM A BIOLOGICAL SAMPLE TAKEN FROM A PATIENT This person is also inventor Name and address: (Family name followed by given name; for a legal entity, full official designation. Telephone No. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.) Facsimile No. 69280 MARCY - L'ETOILE - FRANCE Teleprinter No. Applicant's registration No. with the Office State (that is, country) of residence: **FRANCE** all designated States except the the States indicated in the the United States United States of America of America only Supplemental Box Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S) Name and address: (Family name followed by given name; for a legal entity, full official designation, This person is: The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.) applicant only ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS applicant and inventor inventor only (If this check-box is marked, do not fill in below.) Applicant's registration No. with the Office State (that is, country) of residence: **FRANCE** all designated States except the United States the States indicated in the the United States of America of America only Supplemental Box Further applicants and/or (further) inventors are indicated on a continuation sheet. Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE The person identified below is hereby/has been appointed to act on behalf of the common representative Telephone No. (Family name followed by given name; for a legal entity, full official 01 43 12 84 60 designation. The address must include postal code and name of country.)

29, Rue Cambacérès	01 43 12 84 70		
75008 PARIS France	Teleprinter No.		
	Agent's registration No. with the Office		
Address for correspondence: Mark this check-box where no agent or common representative instead to indicate a special address to which correspondence should be sent.	e is/has been appointed and the space above is used		
Form PCT/RO/101 (first sheet) (March 2001)	See Notes to the reques		

Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)						
If none of the following sub-boxes is used, this sheet should not be included in the request.	If none of the following sub-boxes is used, this sheet should not be included in the request.					
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.) TELLES Jean-Noël 33, Rue Dautancourt 75017 PARIS - FRANCE	This person is: applicant only applicant and inventor inventor only (If this check-box is marked, do not fill in below.)					
	Applicant's registration No. with the Office					
State (that is, country) of nationality: FRANCE State (that is, country) of res	idence: FRANCE					
	nited States the States indicated in the Supplemental Box					
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.) BRUN-VEZINET Françoise 24 Boulevard St Germain 75005 PARIS - FRANCE	This person is: applicant only applicant and inventor inventor only (If this check-box is marked, do not fill in below.) Applicant's registration No. with the Office					
State (that is, country) of nationality: State (that is, country) of res	idence:					
	FRANCE inited States indicated in the Supplemental Box					
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.) DESCAMPS Diane 85 Boulevard Pasteur 75015 PARIS - FRANCE DESCAMPS Diane 87 Boulevard Pasteur Applicant and inventor inventor only (If this check-box is marked, do not fill in below.) Applicant's registration No. with the Office						
State (that is, country) of nationality: State (that is, country) of residence:						
	FRANCE inited States the States indicated in the Supplemental Box					
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.) This person is: applicant only applicant and inventor inventor only (If this check-box is marked, do not fill in below.) Applicant's registration No. with the Office						
State (that is, country) of nationality: State (that is, country) of residence:						
	nited States the States indicated in the Supplemental Box					
Further applicants and/or (further) inventors are indicated on another continuation sheet.						



Box No. V DESIGNATION OF STATES

Mark the applicable check-boxes below; at least one must be marked.

The following designations are hereby made under Rule 4.9(a): (Double-click here if you want all the boxes below checked.)

Regional Patent

- AP ARIPO Patent: GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, MZ Mozambique, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ United Republic of Tanzania, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- EA Eurasian Patent: AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- EP European Patent: AT Austria, BE Belgium, CH & LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, TR Turkey, and any other State which is a Contracting State of the European Patent Convention and of the PCT

National Patent (if other kind of protection or treatment desired, specify on dotted line):

MN Mongolia	AE AG AL AM AT AU AZ BA BB BB BC BB CC CC CC CC CC CC CC CC CC	United Arab Emirates Antigua and Barbuda Albania Armenia Austria Australia Azerbaijan Bosnia and Herzegovina Barbados Bulgaria Brazil Belarus Belize Canada & LI Switzerland and Liechtenstein China Colombia Costa Rica Cuba Czech Republic Germany Denmark Dominica Algeria Estonia Spain Finland United Kingdom Grenada		GE GH GM HR HU ID IL IN IS JP KE KG KP KR LC LL LL LV MA MD MG MK	Georgia Ghana Gambia Croatia Hungary Indonesia Israel India Iceland Japan Kenya Kyrgyzstan Democratic People's Republic of Korea Republic of Korea Republic of Korea Lucia Sri Lanka Liberia Lesotho Lithuania Luxembourg Latvia Morocco Republic of Moldova Madagascar The former Yugoslav Republic of Macedonia Mongolia		NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA	Malawi Mexico Mozambique Norway New Zealand Poland Portugal Romania Russian Federation Sudan Sweden Singapore Slovenia Slovakia Sierra Leone Tajikistan Turkmenistan Turkey Trinidad and Tobago United Republic of Tanzania Ukraine Uganda United States of America Uzbekistan Viet Nam Yugoslavia South Africa Zimbabwe
MN Mongolia ZW Zimbabwe								

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except the designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation (including fees) must reach the receiving Office within the 15-month time limit.)

Box No. VI PRIORI	TY CLAIM					
The priority of the foll	owing earlier application	on(s) is hereby claimed:				
Filing date	Number		Where earlier application	1 is:		
of earlier application (day/month/year)	of earlier application	national application: country	regional application:*	international application:		
item (1) 21 june 1999	99 07855	FRANCE	regional office	receiving office		
item (2)						
item (3)						
item (4)						
item (5)	-					
Further priority cl	aims are indicated in the S	Supplemental Box.		· · · · · · · · · · · · · · · · · · ·		
The receiving Office is re (only if the earlier applied Office) identified above a	cation was filed with the	ransmit to the Internation Office which for the purp	al Bureau a certified copy of oses of this international app	the earlier application(s) plication is the receiving		
all items it	tem item (2)	(3) item (4)	item item (5)	other, see Supplemental Box		
*Where the earlier applicat Industrial Property or one M	ion is an ARIPO application, Member of the World Trade (, indicate at least one countr Organization for which that e	y party to the Paris Convention f earlier application was filed (Rul	for the Protection of		
Box No. VII INTERNA	ATIONAL SEARCHING	AUTHORITY				
international search, indica	te the Authority chosen; the i	two-letter code may be used)	national Searching Authorities ;	are competent to carry out the		
				requested from the International		
Date (day/month/year)	Number		Country (or regional Offic	re)		
10 May 2000	FA 5763	97	OEB			
Box No. VIII DECLAR	ATIONS					
The following declarations a	are contained in Boxes Nos. V of each type of declaration):	TII (i) to (v) (mark the applica	ble check-boxes below and indica	nte in Number of declarations		
Box No. VIII (i) Declaration as to the identify of the inventor :						
Box No. VIII (ii) Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent:						
Box No. VIII (iii) Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application:						
Box No. VIII (iv)	Declaration of inventorsh America)	nip (only for the purposes of th	e designation of the United States	of :		
Box No. VIII (v)	Declaration as to non-pre	eiudicial disclosures or excenti	one to lack of novelty:			

Box No. IX CHECK LIST; LANGUAGE OF FILING							
This international application contains: (a) the following number of sheets in	This international application is accompanied by the for item(s) (mark the applicable check-boxes below and inc						
paper form:	right column the number of each item):						
request (including declaration sheets)	1.	:					
description (excluding sequence listing	2. original separate power of attorney	:					
part) : 15	3. original general power of attorney	:					
claims : 3	4. copy of general power of attorney; reference nu						
abstract : 1	if any:	- ;					
drawings : Sub-total number of sheets :	5. statement explaining lack of signature	:					
sequence listing part of	6. priority document(s) identified in Box No. VI a item(s):						
description (actual number of	7. Translation of international application into	··································					
sheets if filed in paper form, whether or not also filed in	(language):	;					
computer readable form; see	8. separate indications concerning deposited						
(b) below) : Total number of sheets : 23	microorganism or other biological material	:					
Total number of sheets : 23 (b) sequence listing part of description filed in	9. sequence listing in computer readable form (ind						
computer readable form	also type and number of carriers (diskette, CD-l CD-R or other))	ROM,					
(i) only (under Section	(i) copy submitted for the purposes of internati	ional					
801(a)(i)) (ii) ☐ in addition to being	search under Rule 13ter only (and not as pa						
(ii) ☐ in addition to being filed in paper form	the international application)	:					
(under Section	(ii) (only where check-box (b)(i) or (b)(ii) is ma in left column) additional copies including,						
801(a)(ii)) Type and number of carriers (diskette	applicable, the copy for the purposes of	where					
Type and number of carriers (diskette, CD-ROM, CD-R or other) on which the	international search under Rule 13ter	: .					
sequence listing part is contained (additional copies to be indicated under	(iii) together with relevant statement as to the id						
(adaitional copies to be indicated under item 9(ii), in right column):	of the copy or copies with the sequence listi part mentioned in left column	ing :					
	10. \(\text{ other (specify) Search Report} \)	:					
Figure of the drawings which Language of filing of the							
should accompany the abstract:	international application: FRENCH						
	T, AGENT OR COMMON REPRESENTATIVE						
Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading							
the request).							
Paris, 21 june 2000	NONY & ASSOCIATES						
Attorneys of Patent Law							
29, RUE CAMBACÉRÈS TONNELLIER Jean-Claude 75008 PARIS							
For receiving Office use only							
1. Date of actual receipt of the numerted							
 Date of actual receipt of the purported international application: 		2. Drawings:					
3. Corrected date of actual receipt due to later but							
timely received papers or drawings completing received:							
the purported international application:							
4. Date of timely receipt of the required							
corrections under PCT Article 11(2):							
5. International Searching Authority Transmittal of search copy delayed							
(if two or more are competent): ISA / 6. until search fee is paid							
For International Bureau use only							
Date of receipt of the record copy by the International Bureau:							
by the International Bureau.							